These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 28209851)

  • 1. Easier cure for resistant TB.
    Cohen J
    Science; 2017 Feb; 355(6326):677. PubMed ID: 28209851
    [No Abstract]   [Full Text] [Related]  

  • 2. Bedaquiline and Linezolid for Extensively Drug-Resistant Tuberculosis in Pregnant Woman.
    Jaspard M; Elefant-Amoura E; Melonio I; De Montgolfier I; Veziris N; Caumes E
    Emerg Infect Dis; 2017 Oct; 23(10):1731-2. PubMed ID: 28792382
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bedaquiline and Delamanid Combination Treatment of 5 Patients with Pulmonary Extensively Drug-Resistant Tuberculosis.
    Maryandyshev A; Pontali E; Tiberi S; Akkerman O; Ganatra S; Sadutshang TD; Alffenaar JW; Amale R; Mullerpattan J; Topgyal S; Udwadia ZF; Centis R; D'Ambrosio L; Sotgiu G; Migliori GB
    Emerg Infect Dis; 2017 Oct; 23(10):1718-21. PubMed ID: 28758888
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bedaquiline and Delamanid in Children With XDR Tuberculosis: What is prolonged QTc?
    Shah I; Gandhi S; Shetty NS
    Pediatr Infect Dis J; 2020 Jun; 39(6):512-513. PubMed ID: 32032176
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Emergence of Low-level Delamanid and Bedaquiline Resistance During Extremely Drug-resistant Tuberculosis Treatment.
    Polsfuss S; Hofmann-Thiel S; Merker M; Krieger D; Niemann S; Rüssmann H; Schönfeld N; Hoffmann H; Kranzer K
    Clin Infect Dis; 2019 Sep; 69(7):1229-1231. PubMed ID: 30933266
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BPaL approved for multidrug-resistant tuberculosis.
    Burki T
    Lancet Infect Dis; 2019 Oct; 19(10):1063-1064. PubMed ID: 31559963
    [No Abstract]   [Full Text] [Related]  

  • 7. Treatment of Highly Drug-Resistant Pulmonary Tuberculosis.
    Conradie F; Diacon AH; Ngubane N; Howell P; Everitt D; Crook AM; Mendel CM; Egizi E; Moreira J; Timm J; McHugh TD; Wills GH; Bateson A; Hunt R; Van Niekerk C; Li M; Olugbosi M; Spigelman M;
    N Engl J Med; 2020 Mar; 382(10):893-902. PubMed ID: 32130813
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bedaquiline and delamanid in combination for treatment of drug-resistant tuberculosis.
    Mohr E; Ferlazzo G; Hewison C; De Azevedo V; Isaakidis P
    Lancet Infect Dis; 2019 May; 19(5):470. PubMed ID: 31034392
    [No Abstract]   [Full Text] [Related]  

  • 9. Individualizing management of extensively drug-resistant tuberculosis: diagnostics, treatment, and biomarkers.
    Alffenaar JC; Akkerman OW; Anthony RM; Tiberi S; Heysell S; Grobusch MP; Cobelens FG; Van Soolingen D
    Expert Rev Anti Infect Ther; 2017 Jan; 15(1):11-21. PubMed ID: 27762157
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TB Alliance regimen development for multidrug-resistant tuberculosis.
    Murray S; Mendel C; Spigelman M
    Int J Tuberc Lung Dis; 2016 Dec; 20(12):38-41. PubMed ID: 28240571
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Delamanid for Extensively Drug-Resistant Tuberculosis.
    Gupta R; Geiter LJ; Wells CD; Gao M; Cirule A; Xiao H
    N Engl J Med; 2015 Jul; 373(3):291-2. PubMed ID: 26176402
    [No Abstract]   [Full Text] [Related]  

  • 12. Compassionate and optimum use of new tuberculosis drugs.
    Reed C; Mason L; Cox H; Seaworth B; Lessem E; Furin J
    Lancet Infect Dis; 2015 Oct; 15(10):1131. PubMed ID: 26461942
    [No Abstract]   [Full Text] [Related]  

  • 13. Successful treatment of XDR-TB patient in Tanzania: report of the first XDR-TB patient.
    Lyakurwa D; Lyimo J; Mleoh L; Riziki K; Lupinda M; Mpondo BC
    Trop Doct; 2019 Jul; 49(3):224-226. PubMed ID: 30885056
    [TBL] [Abstract][Full Text] [Related]  

  • 14. First case of extensively drug-resistant tuberculosis treated with both delamanid and bedaquiline.
    Tadolini M; Lingtsang RD; Tiberi S; Enwerem M; D'Ambrosio L; Sadutshang TD; Centis R; Migliori GB
    Eur Respir J; 2016 Sep; 48(3):935-8. PubMed ID: 27288039
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Classification of antituberculosis drugs: a new proposal based on the most recent evidence.
    Caminero JA; Scardigli A
    Eur Respir J; 2015 Oct; 46(4):887-93. PubMed ID: 26424519
    [No Abstract]   [Full Text] [Related]  

  • 16. Cost-effectiveness of incorporating bedaquiline into a treatment regimen for MDR/XDR-TB in Germany.
    Wolfson LJ; Gibbert J; Wirth D; Diel R
    Eur Respir J; 2015 Dec; 46(6):1826-9. PubMed ID: 26493796
    [No Abstract]   [Full Text] [Related]  

  • 17. Bedaquiline plus delamanid for XDR tuberculosis.
    Lachâtre M; Rioux C; Le Dû D; Fréchet-Jachym M; Veziris N; Bouvet E; Yazdanpanah Y
    Lancet Infect Dis; 2016 Mar; 16(3):294. PubMed ID: 26973310
    [No Abstract]   [Full Text] [Related]  

  • 18. Compassionate and optimum use of new tuberculosis drugs.
    Matteelli A; D'Ambrosio L; Centis R; Tadolini M; Migliori GB
    Lancet Infect Dis; 2015 Oct; 15(10):1131-1132. PubMed ID: 26461941
    [No Abstract]   [Full Text] [Related]  

  • 19. Long-term bedaquiline-related treatment outcomes in patients with extensively drug-resistant tuberculosis from South Africa.
    Olayanju O; Limberis J; Esmail A; Oelofse S; Gina P; Pietersen E; Fadul M; Warren R; Dheda K
    Eur Respir J; 2018 May; 51(5):. PubMed ID: 29700106
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Proposal for a standardised treatment regimen to manage pre- and extensively drug-resistant tuberculosis cases.
    Caminero JA; Piubello A; Scardigli A; Migliori GB
    Eur Respir J; 2017 Jul; 50(1):. PubMed ID: 28679614
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.